Guerbet : CA T2 2020 impacté par le COVID – La crise n’est pas terminée au Brésil + USA – Le prix pour Dotarem demeurent un challenge – 34 € vs 30.6 €
>T2 en repli de 19% - Reports de commandes liés au COVID - Le CA est en baisse de 19% et environ -20% à tcc. (soit 164.5 M€).Au 30 juin, le CA recule de 9.2% à 363.7 M€ (impact FX : -3.4 M€ / -8.4% à tcc.). En Europe. le CA perd 21% (138.8 M€) : la plupart des pays sont en repli (à noter la poursuite d’effets prix négatif en France, Suisse, et Turquie sur Dotarem®). Sur la Zone Amérique, le CA (102.7 M€) correspond à une baisse de 17.2% (-13.6% à tcc. / baisse de...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.